Ajmani Gaurav S, Liederbach Erik, Kyrillos Alex, Wang Chi-Hsiung, Pinto Jayant M, Bhayani Mihir K
Pritzker School of Medicine, The University of Chicago, Chicago, IL, United States; Division of Surgical Oncology, NorthShore University Health System, Evanston, IL, United States.
Division of Surgical Oncology, NorthShore University Health System, Evanston, IL, United States.
Am J Otolaryngol. 2017 Nov-Dec;38(6):663-667. doi: 10.1016/j.amjoto.2017.08.010. Epub 2017 Aug 30.
Surgery remains the mainstay of treatment for sinonasal melanoma, but it is often difficult to obtain clear, negative margins. Therefore, patients often receive adjuvant radiation therapy (RT), however its impact on overall survival (OS) is not well understood.
Patients with surgically resected sinonasal melanoma were identified from the National Cancer Data Base (NCDB, n=696). Kaplan-Meier curves and parametric survival regression were used to analyze the impact of adjuvant RT on OS from surgery. Adjusted time ratios (aTRs) were computed, with values >1 corresponding to improved survival.
399 (57.3%) patients received adjuvant RT. Those receiving RT tended to be younger but with more advanced disease and greater likelihood of positive margins, compared to those receiving no adjuvant therapy. Median survival was 25.0months for those treated with surgery alone, compared to 28.3months for those receiving adjuvant RT (log-rank P=0.408). When adjusting for potential confounders, there was a trend towards greater survival with adjuvant RT (aTR 1.16, 95%CI 0.98-1.37). RT appeared beneficial in those with stage IVB disease (aTR 2.58, 95%CI 1.40-4.75) but not stage IVA (aTR 1.19, 95%CI 0.88-1.61) or III (aTR 0.85, 95%CI 0.65-1.13) disease. In contrast, there were no differences in impact of RT according to margin status (aTR 1.16 for both positive and negative margins).
Adjuvant therapy does not appear to provide a significant survival benefit in resected sinonasal melanomas regardless of margin status, except those with stage IVB disease. Practitioners should carefully consider the added benefit of adjuvant therapy in these patients.
手术仍然是鼻窦黑色素瘤治疗的主要手段,但通常难以获得切缘阴性且清晰的结果。因此,患者常接受辅助放射治疗(RT),然而其对总生存期(OS)的影响尚未完全明确。
从国家癌症数据库(NCDB,n = 696)中识别出接受手术切除的鼻窦黑色素瘤患者。采用Kaplan-Meier曲线和参数生存回归分析辅助RT对术后OS的影响。计算调整后的时间比(aTRs),其值>1表示生存期改善。
399例(57.3%)患者接受了辅助RT。与未接受辅助治疗的患者相比,接受RT的患者往往更年轻,但疾病分期更晚,切缘阳性的可能性更大。单纯手术治疗的患者中位生存期为25.0个月,接受辅助RT的患者为28.3个月(对数秩检验P = 0.408)。在调整潜在混杂因素后,辅助RT有生存期延长的趋势(aTR 1.16,95%CI 0.98 - 1.37)。RT似乎对IVB期疾病患者有益(aTR 2.58,95%CI 1.40 - 4.75),但对IVA期(aTR 1.19,95%CI 0.88 - 1.61)或III期(aTR 0.85,95%CI 0.65 - 1.13)疾病患者无益处。相比之下,根据切缘状态,RT的影响无差异(切缘阳性和阴性的aTR均为1.16)。
除IVB期疾病患者外,辅助治疗在切除的鼻窦黑色素瘤患者中似乎并未提供显著的生存获益,无论切缘状态如何。临床医生应仔细考虑这些患者辅助治疗的额外获益。